Selling, general and administrative expenses were $39.5 million for the total year 2007, compared with restated full year 2006 of $28.3 million. The year-over-year increase was primarily driven by the inclusion of $6.5 million of expense from the acquisitions and $3.5 million in professional fees and expenses incurred in connection with the review of accounting irregularities at the Sheffield, UK operating unit and related restatements.
The Company's effective tax rate in fiscal 2007 was significantly impacted by a valuation allowance on the net operating loss carry-forward at our Sheffield, UK operating unit of $1.8 million and a $1.4 million reserve for prior year tax positions.
Net loss for total year 2007 was $0.1 million, or $(0.00) per diluted share, compared to restated full year 2006 net income of $18.5 million, or $0.53 per diluted share.
The Company had total cash and cash equivalents of $12.1 million at December 31, 2007, compared to $11.7 million at December 31, 2006.
Brian Moore, President and Chief Executive Officer, stated, "Our
restated financial statements represent the completion of a significant
undertaking. While I am pleased that the restatements were solely
restricted to the Sheffield, UK operating unit, the accounting review and
investigation has been a long and arduous task. We have come out of the
process a stronger company, with new management in Europe as well as
enhanced controls. Throughout all of this, we worked hard to maintain our
excellent customer service and continued to deliver quality product
'/>"/>
| SOURCE Symmetry Medical Inc. Copyright©2008 PR Newswire. All rights reserved |